The 23% organic revenue growth delivered last year reflects only the beginning of the commercialisation phase for many of Kromek's underlying markets. Visibility into the new fiscal period is at an all time high and free cash flow breakeven is in sight. All of this is at odds with the share price near the all time low. Buy.
27 Jun 2019
Cenkos: Kromek Group Plc - Solid track record of organic expansion
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Cenkos: Kromek Group Plc - Solid track record of organic expansion
Kromek Group Plc (KMK:LON) | 6.8 0 0.0% | Mkt Cap: 43.9m
- Published:
27 Jun 2019 -
Author:
Cavendish Research -
Pages:
6
The 23% organic revenue growth delivered last year reflects only the beginning of the commercialisation phase for many of Kromek's underlying markets. Visibility into the new fiscal period is at an all time high and free cash flow breakeven is in sight. All of this is at odds with the share price near the all time low. Buy.